FDA approves Sotyktu for adults with active psoriatic arthritis

The U.S. Food and Drug Administration has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.
Healio

FDA approves deucravacitinib for adults with active psoriatic arthritis

The FDA has approved deucravacitinib for adults with active psoriatic arthritis, according to a press release from Bristol ...
GlobalData on MSN

BMS gains FDA approval for Sotyktu in psoriatic arthritis treatment

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.
Clinical Pain Advisor

Sotyktu Receives FDA Approval for Adults With Active Psoriatic Arthritis

Oral TYK2 inhibitor deucravacitinib receives FDA approval for active psoriatic arthritis based on significantly improved ACR20 response rates.
Medscape

Pediatric Rheumatologist Explains Many New Updates to ACR’s Juvenile Idiopathic Arthritis Guidelines

The new draft guidelines favor earlier DMARD therapy with ‘much decreased reliance on glucocorticoids that have several side effects in growing children,’ said rheumatologist Susan Shenoi, MS.
Medscape

Will New Polymyalgia Rheumatica Treatments Lessen Need for ‘Improvisation’?

The therapeutic landscape for polymyalgia rheumatica (PMR) has grown and will grow further, allowing prolonged use of glucocorticoids (GCs) to be minimized, Anisha B. Dua, MD, MPH, of Feinberg School ...
rmdopen.bmj

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies

Objective To present updated integrated safety analyses of bimekizumab in patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). Methods Safety data pooled from six phase IIb/III ...